Video: Knock on Wood| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: hospital

Researchers Seek to Predict & Prevent Rheumatoid Arthritis

Jeffrey A. Sparks, MD, MMSc, & Kevin D. Deane, MD, PhD  |  June 21, 2018

Preventing adverse outcomes in individuals who have rheumatic diseases is a daily goal for rheumatologists. For example, rheumatologists prescribe medications and perform screening to prevent erosions in rheumatoid arthritis (RA), renal failure in systemic lupus erythematosus and flares across all diseases. Many of these actions are classified as secondary or tertiary prevention, because individuals have…

Filed under:Rheumatoid Arthritis Tagged with:lifestyleMetricsrisk assessmentRisk Factors

Dr. Ellen M. Gravallese In the Spotlight

Gretchen Henkel  |  June 21, 2018

Robert Finberg, MD, chair of medicine at the University of Massachusetts (UMass) in Worcester, describes Ellen M. Gravallese, MD, as one of a dying breed: a quadruple-threat physician who excels in basic science research, clinical care, teaching and administration. Dr. Gravallese holds the Myles J. McDonough Chair in Rheuma­tology, is professor of medicine and serves…

Filed under:From the CollegeProfiles Tagged with:Dr. Ellen M. Gravallese

Lightspring / Shutterstock.com

When & How to Talk to Your Patients About Their Gender & Sex

Susan Bernstein  |  June 21, 2018

How do you ask a new patient about sex and gender—or know which pronoun to use? Keep the conversation straightforward and respectful to put everyone at ease, says Morgan Orndorff, a transgender man who works as an administrator at a major academic medical center. “Everyone is a little different in terms of their sensitivity level”…

Filed under:Patient PerspectiveProfessional Topics Tagged with:GenderLGBTQsex

Certolizumab Pegol Receives FDA Approval for Plaque Psoriasis

Michele B. Kaufman, PharmD, BCGP  |  June 18, 2018

On the basis of data from multiple clinical trials, the FDA has approved certolizumab pegol for treating moderate to severe plaque psoriasis…

Filed under:Drug Updates Tagged with:Certolizumab PegolFDAFDA approvalplaque psoriasisPsoriasisU.S. Food and Drug Administration (FDA)

Fed Up with Rising Costs, Big U.S. Firms Dig Into Healthcare

Caroline Humer  |  June 12, 2018

SAN JOSE, Calif., (Reuters)—At its Silicon Valley headquarters, network gear maker Cisco Systems Inc. is going to unusual lengths to take control of the relentless increase in its U.S. healthcare costs. The company is among a handful of large American employers who are getting more deeply involved in managing their workers’ health instead of looking…

Filed under:Legislation & AdvocacyProfessional Topics Tagged with:Cisco Systems Inc.Healthcarehealthcare cost

FDA Approves Denosumab for Glucocorticoid-Induced Osteoporosis

Michele B. Kaufman, PharmD, BCGP  |  June 11, 2018

Denosumab is now approved to treat adults with glucocorticoid-induced osteoporosis…

Filed under:ConditionsDrug UpdatesOsteoarthritis and Bone Disorders Tagged with:denosumabFDAGlucocorticoid-Induced OsteoporosisOsteoporosisosteoporosis treatmentsU.S. Food and Drug Administration (FDA)

ACR’s Affiliate Society Council Reports Solid Gains in Advocacy Efforts

Gretchen Henkel  |  June 7, 2018

It’s May, and soon, most state legislatures will be adjourning for the remainder of the year. Joseph Cantrell, JD, senior manager of state affairs for the ACR, who tracks the progress of state and federal patient care legislation, reports that several states saw solid gains during 2018 state sessions, which typically run from January to…

Filed under:Legislation & Advocacy Tagged with:Affiliate Society Council (ASC)Joseph Cantrellpharmacy benefit managers (PBMs)state legislation

FDA Updates Ixekizumab Label to Include Genital Area Psoriasis

Michele B. Kaufman, PharmD, BCGP  |  June 6, 2018

Ixekizumab is the first agent approved by the FDA for treating plaque psoriasis to include labeling for psoriasis in the genital area…

Filed under:ConditionsDrug Updates Tagged with:FDAgenital psoriasisixekizumabPsoriasisU.S. Food and Drug Administration (FDA)

Spine Surgery May not Be Needed to Ease Back Pain from Osteoporosis

Lisa Rapaport  |  June 3, 2018

(Reuters Health)—Patients with acute pain from osteoporosis damage to the spine don’t experience any more relief from surgery to inject cement into cracked or broken vertebrae than they would with a sham procedure, a recent trial in The Netherlands suggests. All of the patients in the experiment had compression fractures, which can happen when osteoporosis…

Filed under:ConditionsOsteoarthritis and Bone Disorders Tagged with:Back painCristina FiranescuEvan DaviesOsteoporosisspine surgery

Gap in Regulating Biotech Drug Copies Prompts WHO to Step In

Ben Hirschler  |  May 31, 2018

LONDON (Reuters)—Cut-price copies of expensive biotech drugs promise to slash the cost of treating serious diseases, including cancer, in rich and poor countries alike -but uneven regulation has created a lopsided market. Now the World Health Organization (WHO) is stepping in to assess the quality of such so-called biosimilars, offering a global stamp of approval…

Filed under:Drug Updates Tagged with:Biosimilarsbiotech drug copiesglobal stamp of approvalPfizer Inc.regulation gapWorld Health Organization (WHO)

  • « Previous Page
  • 1
  • …
  • 151
  • 152
  • 153
  • 154
  • 155
  • …
  • 323
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences